ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now ...

Epidermolysis Bullosa, also colloquially known as butterfly skin disease, a rare genetic condition that makes your skin very ...

Over 20 foreign nationals who themselves endured years of captivity in Iran on Wednesday urged Sweden to step up efforts to ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

New research reveals the potential of drugs that have been on the market for decades to treat diseases other than those for ...

In this week’s edition of The Prototype, we look at quantum computing for image recognition, a gene therapy using a patient’s ...

It’s so special to be playing for a purpose, the purpose being this incredible mission,” Eddie Vedder tells TODAY.com.

A Mayo woman who suffers from a rare, genetic skin disease will abseil from the roof of Croke Park to fundraise for a charity ...

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S.